Coronary Artery Disease
Conditions
Keywords
prognosis, all-cause mortality, myocardial infarction, stroke
Brief summary
The purpose of this study is to investigate the change of total cholesterol content of erythrocyte membranes (CEM) in patients with coronary artery disease treated with secondary prevention drugs, and the correlation with the prognosis.
Detailed description
In this clinical trial, plasma samples, the red cells and associated clinical data of patients with coronary artery disease were collected from Department of Cardiology of Lu'an Shili Hospital and the First Affiliated Hospital of Jinan University. Blood samples collected from all the participants at baseline (prior to the follow-up) and the time points of follow-up were placed into ordinary test tubes and stored at 4°C for less than 4 hours. After centrifuged, plasma and erythrocyte membranes was separated and stored at -80°C. The change of total cholesterol content of erythrocyte membranes (CEM) was measured. A follow-up form was designed according to the research purpose and discussed among the team members. The follow-up was performed through telephone by the trained investigators with good communication skills and knowledge on the diagnosis and treatment of coronary artery disease. Patients were followed up every six months from the day of discharge. The results of the follow-up were entered into the database, a process that was carried out by a designated person and double-checked by an independent person. The primary clinical endpoints were composite atherosclerotic cardiovascular disease outcomes, defined as nonfatal myocardial infarction, nonfatal stroke, or cardiovascular mortality. Secondary clinical endpoints were revascularization, including percutaneous coronary intervention and coronary artery bypass grafting, and Class IV heart failure requiring hospitalization.
Interventions
None listed
Sponsors
First Affiliated Hospital of Jinan University
Lu'an Municipal Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent; * First diagnosis of CAD through CAG; * Aged 45-70.
Exclusion criteria
* Patients with severe liver or kidney damage; * Taking statins within the last 3 months; * Patients who had been diagnosed with CAD and treated with oral medication; * Chronic diseases of the blood system; * Familial hyperlipidemia patients; * Patients combining autoimmune disease; * Patients combining acute infectious disease; * Patients who undertaken surgery or injury; * Patients who combining cancer; * Patients who taking glucocorticoid replacement therapy; * Abnormal red blood cell (RBC) count (M: \<4.0 or \>5.5 × 1012/L; F: \<3.5 or \>5.0 × 1012/L) or abnormal hemoglobin (M: \<120 or \>160 g/L; F: \<110 or \>150 g/L).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the change of CEM | before and 6-, 12-, 18-, 24- month after follow-up | the change of CEM |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| heart failure | 24- months | heart failure |
| all-cause mortality | 24- months | all-cause mortality |
| coronary revascularization | 24- months | coronary revascularization |
| non-fatal myocardial infarction | 24- months | non-fatal myocardial infarction |
| non-fatal stroke | 24- months | non-fatal stroke |
| cardiovascular mortality | 24- months | cardiovascular mortality |
Outcome results
None listed